Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$2.46 -4.3%	$2.57	$7.96 ▼ $24.15	$12.41M	0.63	15,685 shs	10,797 shs
CLDI Calidi Biotherapeutics	$1.74 +2.4%	$5.37	$1.61 ▼ $46.68	$5.14M	1.15	649,763 shs	533,723 shs
IBIO iBio	$0.79 +1.9%	$0.73	$0.56 ▼ $6.89	$15.26M	0.6	1.39 million shs	411,981 shs
RDHL Redhill Biopharma	$1.31 +0.8%	$1.72	$1.06 ▼ $12.50	$2.98M	4.18	152,462 shs	32,543 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	-4.28%	+8.37%	-4.28%	-11.83%	-86.10%
CLDI Calidi Biotherapeutics	+2.35%	-67.17%	-80.38%	-64.67%	-90.40%
IBIO iBio	+1.89%	+6.72%	+3.98%	-3.30%	-61.03%
RDHL Redhill Biopharma	+0.77%	-3.68%	-35.15%	-28.80%	-88.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLDI Calidi Biotherapeutics	0.7661 of 5 stars	0.0	4.0	0.0	0.0	2.3	0.0	0.6
IBIO iBio	2.1539 of 5 stars	3.5	0.0	0.0	0.0	3.1	0.0	0.6
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVR AlloVir	0.00	N/A	N/A	N/A
CLDI Calidi Biotherapeutics	0.00	N/A	N/A	N/A
IBIO iBio	3.00	Buy	$5.00	532.11% Upside
RDHL Redhill Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RDHL, CLDI, ALVR, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	($2.32) per share	N/A
IBIO iBio	$375K	41.46	N/A	N/A	$1.41 per share	0.56
RDHL Redhill Biopharma	$8.04M	0.37	N/A	N/A	($3.66) per share	-0.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVR AlloVir	-$190.42M	-$20.23	N/A	∞	N/A	N/A	-71.03%	-61.27%	11/10/2025 (Estimated)
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
RDHL Redhill Biopharma	-$8.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVR AlloVir	N/A	86.78	86.78
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
IBIO iBio	0.05	1.76	1.76
RDHL Redhill Biopharma	N/A	0.54	0.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVR AlloVir	66.05%
CLDI Calidi Biotherapeutics	12.53%
IBIO iBio	7.90%
RDHL Redhill Biopharma	7.20%

Insider Ownership

Company	Insider Ownership
ALVR AlloVir	32.07%
CLDI Calidi Biotherapeutics	6.70%
IBIO iBio	0.58%
RDHL Redhill Biopharma	6.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	Optionable
CLDI Calidi Biotherapeutics	38	3.03 million	20.04 million	N/A
IBIO iBio	100	19.66 million	9.82 million	N/A
RDHL Redhill Biopharma	210	2.30 million	2.14 million	No Data

RDHL, CLDI, ALVR, and IBIO Headlines

Recent News About These Companies

RedHill awarded $1.82M in legal costs and expenses in action against Kukbo

August 20 at 5:44 PM | msn.com

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

August 20 at 9:00 AM | prnewswire.com

RedHill Biopharma receives Talicia licensing payments totaling $1.1M

August 19, 2025 | msn.com

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

August 18, 2025 | prnewswire.com

RedHill Biopharma Granted Nasdaq Compliance Extension

August 14, 2025 | msn.com

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

July 21, 2025 | prnewswire.com

RDHL - Redhill Biopharma Ltd ADR Trailing Returns - Morningstar

July 18, 2025 | morningstar.comM

RedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide study

July 2, 2025 | msn.com

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

July 1, 2025 | prnewswire.com

RedHill Biopharma Ltd. (RDHL) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RedHill Biopharma Ltd. (RDHL) Income Statement - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025 | prnewswire.com

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025 | prnewswire.com

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

April 28, 2025 | prnewswire.com

RedHill Biopharma receives non-compliance letter from Nasdaq

April 18, 2025 | markets.businessinsider.com

RedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

April 18, 2025 | finanznachrichten.de

RedHill Biopharma announces publication in journal on Opaganib

April 17, 2025 | markets.businessinsider.com

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

April 17, 2025 | prnewswire.com

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

April 16, 2025 | prnewswire.com

RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

April 10, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL, CLDI, ALVR, and IBIO Company Descriptions

AlloVir NASDAQ:ALVR

$2.46 -0.11 (-4.28%)

As of 08/21/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Calidi Biotherapeutics NYSE:CLDI

$1.74 +0.04 (+2.35%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.76 +0.02 (+1.09%)

As of 08/22/2025 07:42 PM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

iBio NYSE:IBIO

$0.79 +0.01 (+1.89%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.78 -0.01 (-1.01%)

As of 08/22/2025 07:50 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Redhill Biopharma NASDAQ:RDHL

$1.31 +0.01 (+0.77%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.36 +0.05 (+3.51%)

As of 08/22/2025 08:00 PM Eastern

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time